TY - GEN AB - Our understanding of the neuroimmune response to alcohol exposure and its role in the development and maintenance of Alcohol Use Disorder (AUD) has provided an avenue for discovering potential pharmacotherapies. We tested 28 compounds (many of which target inflammatory processes) for their ability to reduce drinking in High Drinking in the Dark mice (HDID), a unique genetic model of drinking to intoxication. Many (11 out of 14) compounds that reduced binge-like drinking in HDID mice had one thing in common; they increased anti-inflammatory signaling in the periphery. We found that apremilast, an FDA approved phosphodiesterase type 4 (PDE4) and tumor necrosis factor alpha (TNFa) inhibitor used for the treatment of psoriasis, significantly reduced binge-like drinking and blood alcohol levels in both HDID-1 and HDID-2 mice (0, 20, 40mg/kg; n=11- 13/sex/line/dose; p's < 0.05 for all). AD - Oregon Health and Science University AD - Oregon Health and Science University AD - Oregon Health and Science University AU - Medrano, J. AU - Grigsby, K. AU - Ozburn, A. DA - 2022-04-22 DO - 10.6083/w37637734 DO - DOI ID - 9642 KW - Binge Drinking KW - inflammatory signaling KW - apremilast L1 - https://digitalcollections.ohsu.edu/record/9642/files/ResearchWeek2022-AbstractTemplate_for_IR__6_.pdf L2 - https://digitalcollections.ohsu.edu/record/9642/files/ResearchWeek2022-AbstractTemplate_for_IR__6_.pdf L4 - https://digitalcollections.ohsu.edu/record/9642/files/ResearchWeek2022-AbstractTemplate_for_IR__6_.pdf LK - https://digitalcollections.ohsu.edu/record/9642/files/ResearchWeek2022-AbstractTemplate_for_IR__6_.pdf N2 - Our understanding of the neuroimmune response to alcohol exposure and its role in the development and maintenance of Alcohol Use Disorder (AUD) has provided an avenue for discovering potential pharmacotherapies. We tested 28 compounds (many of which target inflammatory processes) for their ability to reduce drinking in High Drinking in the Dark mice (HDID), a unique genetic model of drinking to intoxication. Many (11 out of 14) compounds that reduced binge-like drinking in HDID mice had one thing in common; they increased anti-inflammatory signaling in the periphery. We found that apremilast, an FDA approved phosphodiesterase type 4 (PDE4) and tumor necrosis factor alpha (TNFa) inhibitor used for the treatment of psoriasis, significantly reduced binge-like drinking and blood alcohol levels in both HDID-1 and HDID-2 mice (0, 20, 40mg/kg; n=11- 13/sex/line/dose; p's < 0.05 for all). PB - Oregon Health and Science University PY - 2022-04-22 T1 - Modulatory role of apremilast on binge-like drinking and brain cytokine levels TI - Modulatory role of apremilast on binge-like drinking and brain cytokine levels UR - https://digitalcollections.ohsu.edu/record/9642/files/ResearchWeek2022-AbstractTemplate_for_IR__6_.pdf Y1 - 2022-04-22 ER -